Anavex Life Sciences Corp (AVXL)

[kevli33]

Keep in mind:

Less Dementia Risk with Intensive Blood Pressure Treatments

In a new study, treating blood pressure more aggressively lowered odds of developing mild cognitive impairment, a gateway to dementia. CBS News chief medical correspondent Dr. Jon LaPook explains.

http://www.alzheimersweekly.com/2018/07/less-dementia-risk-with-intensive-blood.html

NEW YORK, NY – January 16, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases today reports that the peer-reviewed scientific journal The Journal of Clinical Hypertension [1] has published a post-hoc analysis of blood pressure data collected during the Phase 2a study in mild-to-moderate Alzheimer’s disease patients demonstrating that ANAVEX®2-73 seems to normalize systolic blood pressure (SBP) in a patient population with risk for hypertension.

https://www.anavex.com/anavex-life-sciences-reports-potential-normalization-of-hypertension-with-anavex2-73-published-in-the-journal-of-clinical-hypertension/

" rel="nofollow" target="_blank">https://www.youtube.com/watch?v=